Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Elkhashab, Magdy
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a	Completed	3	407	Europe, Canada, US, RoW	Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir	Eiger BioPharmaceuticals	Hepatitis Delta Virus	10/22	03/23
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	871	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis	Active, not recruiting	2b	357	Europe, Canada, US, RoW	belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo	Galectin Therapeutics Inc., Galectin Therapeutics Inc	Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis	12/24	12/24